Cerulein

Imatinib mesylate (IMT) was procured from Sigma Aldrich, USA. Cerulein was obtained from Ana Spec, France. TGF-β1 was procured from Bio-legend, USA. The antibodies viz. β-actin (Catalogue no. sc-47778), Collagen1a (Catalogue no. sc-393573), Collagen3a (Catalogue no. sc-271249), α-SMA (Catalogue no. sc-53142), CTGF (Catalogue no. sc-373936), TGF-β1 (Catalogue no. sc-146), DDR2 (Catalogue no. sc-81707), pSmad2/3 (Catalogue no. #8828), Smad2/3 (Catalogue no. #8685), pDDR1 (Catalogue no. #14531), DDR1 (Catalogue no. #5583), pNF-κB (Catalogue no. #3033), NF-κB (Catalogue no. #8242) were procured from Santa Cruz Biotechnology Ltd and Cell Signaling Technology, USA. The ELISA kits of TGF-β, IL-1β, IL-6 and TNF-α (Catalogue no. TGF-β: 88–8350, IL-1β: 88–7013, IL-6: 88- 7064, and TNF-α: 88–7324) were obtained from eBioscience, USA.

Eighteen C57BL/6 male mice weighing 20–25 g were purchased from Shanghai Model Organisms Center (Shanghai, China). Hyperlipidemia was induced by the intraperitoneal administration of P-407 (P2443, Sigma-Aldrich) in PBS at a dose of 500 mg/kg three times a week. On day 30, the hyperlipidemic mice received an intraperitoneal injection of cerulein (AnaSpec, Los Angeles, CA, USA) in PBS at a dose of 50 μg/kg every hour for a total of 10 injections. Then blood samples were collected from the tail vein and centrifuged for 15 min at 3,500 g, serum was obtained for further analysis.
To evaluate the effect of hnRNPA2B1 de-neddylation in HTGP mice, MLN4924 (30 mg/kg body weight) was administered subcutaneously, twice a week for two weeks. Animals were subsequently euthanized using intraperitoneal pentobarbital (100 mg/kg; P-010, Sigma-Aldrich).